Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma
Objective: Multiple myeloma (MM) is currently incurable due to refractory disease relapse even under novel anti-myeloma treatment. In silico studies are effective for key decision making during clinicopathological battles against the chronic course of MM. The aim of this present in silico study was...
Main Authors: | Mehdi Ghasemi, Semih Alpsoy, Seyhan Türk, Ümit Y. Malkan, Şükrü Atakan, İbrahim C. Haznedaroğlu, Gürsel Güneş, Mehmet Gündüz, Burak Yılmaz, Sezgin Etgül, Seda Aydın, Tuncay Aslan, Nilgün Sayınalp, Salih Aksu, Haluk Demiroğlu, Osman İ. Özcebe, Yahya Büyükaşık, Hakan Göker |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2016-11-01
|
Series: | Turkish Journal of Hematology |
Subjects: | |
Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-98105 |
Similar Items
-
Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01) -
Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission
by: Mürüvvet Seda Aydın, et al.
Published: (2017-03-01) -
The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice
by: Ümit Yavuz Malkan, et al.
Published: (2016-11-01) -
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01) -
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study
by: Hakan Savlı, et al.
Published: (2015-07-01)